7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,740.81

+534.98

+0.69%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

OTC Markets OTCQB - Delayed Quote USD

CytoDyn Inc. (CYDY)

0.2200 -0.0100 (-4.35%)

At close: October 30 at 4:00:00 PM EDT

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO

MarketBeat 12d ago

CYDY
-4.35%
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer

GlobeNewswire 12d ago

CYDY
-4.35%
CytoDyn to Host Investor Webcast

GlobeNewswire 16d ago

CYDY
-4.35%
NTRA
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026

GlobeNewswire 23d ago

CYDY
-4.35%
CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer

MarketBeat 1mo ago

CYDY
-4.35%
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab

GlobeNewswire 1mo ago

CYDY
-4.35%
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease

GlobeNewswire 4mo ago

CYDY
-4.35%
CytoDyn to Present at the LD Micro Invitational XVI

GlobeNewswire 5mo ago

CYDY
-4.35%
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer

GlobeNewswire 6mo ago

CYDY
-4.35%
CytoDyn to Host Investor Webcast

GlobeNewswire 6mo ago

CYDY
-4.35%
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026

GlobeNewswire 6mo ago

CYDY
-4.35%
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study

GlobeNewswire 6mo ago

CYDY
-4.35%

Performance Overview

Return	CYDY	S&P 500 (^GSPC)
YTD	-21.43%	+10.73%
1-Year	-8.33%	+11.11%
3-Year	+37.50%	+81.91%

Mobilize your Website

View Site in Mobile | Classic

Share by: